https://emeraldglasses.com/portfolio/pre-approval-access-can-compassion-business-and-medicine-coexist/2020-11-06T16:53:15+00:00https://emeraldglasses.com/portfolio/phase-1-trials-rvsv-ebola-vaccine-africa-and-europe/2020-11-06T16:47:17+00:00https://emeraldglasses.com/portfolio/vaccines-consistency-approach-project-epaa-initiative/2020-11-06T16:52:58+00:00https://emeraldglasses.com/portfolio/strategies-facilitating-regulatory-pathways/2020-11-06T16:53:05+00:00https://emeraldglasses.com/portfolio/incorporating-lean-principles-pharmaceutical-qc-laboratory-design-building-design/2020-11-06T16:52:43+00:00https://emeraldglasses.com/portfolio/designing-labs-lean-operation/2020-11-06T16:52:51+00:00https://emeraldglasses.com/portfolio/glp-requirements-and-current-practices/2020-11-06T16:52:35+00:00https://emeraldglasses.com/portfolio/transcutaneous-immunization-domestic-animals-opportunities-and-challenges/2020-11-06T16:52:27+00:00https://emeraldglasses.com/portfolio/transcutaneous-immunization-bacterial-adp-ribosylating-exotoxins-subunits-and/2020-11-06T16:52:04+00:00https://emeraldglasses.com/portfolio/transcutaneous-immunization-using-colonization-factor-and-heat-labile-enterotoxin/2020-11-06T16:52:20+00:00https://emeraldglasses.com/portfolio/dry-formulation-transcutaneous-immunization/2020-11-06T16:52:11+00:00https://emeraldglasses.com/portfolio/transcutaneous-immunization-enteric-vaccines/2020-11-06T16:51:49+00:00https://emeraldglasses.com/portfolio/principles-transcutaneous-immunization-using-cholera-toxin-adjuvant/2020-11-06T16:51:57+00:00https://emeraldglasses.com/portfolio/immunostimulatory-oligodeoxynucleotides-promote-protective-immunity-and-provide/2020-11-06T16:51:34+00:00https://emeraldglasses.com/portfolio/advances-vaccine-delivery-transcutaneous-immunisation/2020-11-06T16:51:42+00:00https://emeraldglasses.com/portfolio/transcutaneous-immunization-bacterial-adp-ribosylating-exotoxins-antigens-and/2020-11-06T16:51:24+00:00https://emeraldglasses.com/portfolio/transcutaneous-immunization-cholera-toxin-protects-mice-against-lethal-mucosal-toxin/2020-11-06T16:53:23+00:00https://emeraldglasses.com/portfolio/failure-p-strain-mice-respond-vaccination-against-schistosomiasis-correlates-impaired/2020-11-06T16:27:13+00:00https://emeraldglasses.com/portfolio/genetic-immunization-glycoprotein-63-cdna-results-helper-t-cell-type-1-immune-response/2020-11-06T16:27:34+00:00https://emeraldglasses.com/portfolio/partially-protective-vaccination-permits-development-latency-normally-virulent-strain/2020-11-06T16:28:11+00:00https://emeraldglasses.com/portfolio/infection-mice-lacking-common-cytokine-receptor-gamma-chain-gammac-reveals-unexpected/2020-11-06T16:28:57+00:00https://emeraldglasses.com/portfolio/decreased-resistance-tnf-receptor-p55-and-p75-deficient-mice-chronic-toxoplasmosis/2020-11-06T16:30:59+00:00https://emeraldglasses.com/portfolio/mice-deficient-nuclear-factor-nf-kappa-bp52-present-defects-humoral-responses-germinal/2024-12-12T12:55:19+00:00https://emeraldglasses.com/portfolio/cytokines-determinants-disease-and-disease-interactions/2020-11-06T16:31:30+00:00https://emeraldglasses.com/portfolio/role-dendritic-cells-initiation-host-resistance-toxoplasma-gondii/2020-11-06T16:32:14+00:00https://emeraldglasses.com/portfolio/vivo-microbial-stimulation-induces-rapid-cd40-ligand-independent-production/2020-11-06T16:31:52+00:00https://emeraldglasses.com/portfolio/immune-responses-mice-deficient-ly-gdi-lymphoid-specific-regulator-rho-gtpases/2020-11-06T16:32:46+00:00https://emeraldglasses.com/portfolio/leishmania-major-infected-c3h-mice-treated-anti-il-12-mab-develop-do-not-maintain-th2/2020-11-06T16:33:19+00:00https://emeraldglasses.com/portfolio/analysis-granuloma-formation-double-cytokine-deficient-mice-reveals-central-role-il-10/2020-11-06T16:33:50+00:00https://emeraldglasses.com/portfolio/mechanisms-innate-resistance-toxoplasma-gondii-infection/2020-11-06T16:34:16+00:00https://emeraldglasses.com/portfolio/perforin-mediated-cytolysis-plays-limited-role-host-resistance-toxoplasma-gondii/2020-11-06T16:34:40+00:00https://emeraldglasses.com/portfolio/critical-roles-bcl-3-oncoprotein-t-cell-mediated-immunity-splenic-microarchitecture/2020-11-06T16:35:15+00:00https://emeraldglasses.com/portfolio/inducible-nitric-oxide-essential-host-control-persistent-not-acute-infection/2020-11-06T16:35:46+00:00https://emeraldglasses.com/portfolio/role-natural-killer-cells-innate-resistance-protozoan-infections/2020-11-06T16:36:09+00:00https://emeraldglasses.com/portfolio/toxoplasma-gondii-evidence-interleukin-12-dependent-and-independent-pathways/2020-11-06T16:36:47+00:00https://emeraldglasses.com/portfolio/absence-endogenous-ifn-gamma-mice-develop-unimpaired-il-12-responses-toxoplasma-gondii/2020-11-06T16:55:30+00:00https://emeraldglasses.com/portfolio/role-il-12-regulation-t-helper-cell-subsets-vivo-lessons-experimental-cutaneous/2020-11-06T16:55:19+00:00https://emeraldglasses.com/portfolio/role-cd4-nk11-t-lymphocytes-major-histocompatibility-complex-class-ii-independent/2020-11-06T16:55:01+00:00https://emeraldglasses.com/portfolio/absence-endogenous-il-10-mice-acutely-infected-toxoplasma-gondii-succumb-lethal-immune/2020-11-06T16:55:10+00:00https://emeraldglasses.com/portfolio/interferon-consensus-sequence-binding-protein-deficient-mice-display-impaired/2020-11-06T16:54:53+00:00https://emeraldglasses.com/portfolio/il-12-required-natural-killer-cell-activation-and-subsequent-t-helper-1-cell/2020-11-06T16:41:21+00:00https://emeraldglasses.com/portfolio/role-innate-immune-response-th1-cell-development-following-leishmania-major-infection/2020-11-06T16:43:42+00:00https://emeraldglasses.com/portfolio/interaction-between-innate-and-acquired-immune-system-following-infection-different/2020-11-06T16:44:01+00:00https://emeraldglasses.com/portfolio/adjuvant-effect-interleukin-12-vaccine-against-leishmania-major/2020-11-06T16:43:22+00:00https://emeraldglasses.com/portfolio/natural-killer-cells-are-source-interferon-gamma-drives-differentiation-cd4-t-cell/2020-11-06T16:41:55+00:00https://emeraldglasses.com/portfolio/regulations-and-science-common-sense-approaches-accelerating-patient-access-novel-gene/2024-12-12T12:55:57+00:00